DBV Technologies SA, of Bagneux, France, disclosed the completion of phase I or part A of the Viaskin Milk Efficacy and Safety phase I/II study known as Miles. Read More
Advanced Accelerator Applications SA (AAA), of Saint-Genis-Pouilly, France, signed a distribution agreement for Lutathera (lutate; 177Lutetium DOTA0 Tyr3-Octreotate) in Japan with Fujifilm RI Pharma Co. Ltd., of Tokyo. Read More
PDL Biopharma Inc., of Incline Village, Nev., said it entered a credit agreement with Careview Communications Inc. to provide the firm with up to $40 million of secured debt financing in two tranches of $20 million, based upon the achievement of specified milestones. Read More
HONG KONG – Chinese researchers have discovered a novel nonasaccharide molecule – a nine-unit sugar chain – with potent anticoagulant activity that could avoid adverse effects, paving the way for the development of better treatments for thromboembolic diseases, they reported in the June 22, 2015, early online issue of Proceedings of the National Academy of Sciences. Read More
With a progressive strategy that's "building an ecosystem," Biondvax Pharmaceuticals Ltd. offered upbeat preliminary results from the BVX-006 phase II trial gauging the worth of M-001 in the Ness Ziona, Israel-based firm's quest for a universal influenza vaccine, and analyst Ashok Kumar at Aegis Capital Corp. tagged what could be alluring prospects for would-be partners or buyers of the firm. Read More
Roche AG is planning early 2016 regulatory filings to seek approvals for ocrelizumab, a twice-yearly injectable multiple sclerosis (MS) therapy, after two phase III studies showed that it significantly reduced relapses and disability progression vs. Rebif (beta interferon 1a, EMD Serono Inc. and Pfizer Inc.) for people with relapsing MS, the most common form of the disease. Read More
Biosimilars in the U.S. are far from the standard fare they're becoming in some countries, but the FDA expects them to be a steady portion of its workload. Read More
SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC). Read More
